Sejung Park

Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19–14)

Choong‐kun Lee, Hong Jae Chon, Jaekyung Cheon et al. · ˜The œLancet. Gastroenterology & hepatology · 2022 · 124 citations · Full text

Medicine, Oncology, Pharmacology +12

A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer

Choong‐kun Lee, Sun Young Rha, Hyo Song Kim et al. · Nature Communications · 2022 · 54 citations · Full text

Medicine, Oncology, Pharmacology +15

Trastuzumab Combined With Ramucirumab and Paclitaxel in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Advanced Gastric or Gastroesophageal Junction Cancer

Chang Gon Kim, Minkyu Jung, Hyo Song Kim et al. · Journal of Clinical Oncology · 2023 · 44 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Prior antibiotic administration disrupts anti-PD-1 responses in advanced gastric cancer by altering the gut microbiome and systemic immune response

Chang Gon Kim, June‐Young Koh, Su‐Jin Shin et al. · Cell Reports Medicine · 2023 · 42 citations · Full text

Medicine, Oncology, Pharmacology +17

Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer

Hyung Soon Park, Woo Sun Kwon, Sejung Park et al. · Journal for ImmunoTherapy of Cancer · 2019 · 38 citations · Full text

Life Sciences, Immunology, Oncology +17